Download Files:
Products Details
Product Description
– L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson’s disease research[1][2][3].
Web ID
– HY-N0304A
Shipping
– Room temperature
Applications
– Neuroscience-Neurodegeneration
Molecular Formula
– C9H10NNaO4
References
– [1]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10.|[2]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(4):273-80. Epub 2007 Nov 7.|[3]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson’s Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[4]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54(2):330-5.
CAS Number
– 63302-01-2
Molecular Weight
– 219.17
SMILES
– O=C([C@H](CC1=CC=C(C(O)=C1)O)N)O[Na]
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– Dopamine Receptor;Endogenous Metabolite
Isoform
– Human Endogenous Metabolite
Pathway
– GPCR/G Protein;Metabolic Enzyme/Protease;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
